Author

A. Le Naour

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Coste· 1 shared A. Martinez· 1 shared A. Rossary· 1 shared B. Couderc· 1 shared B. Thibault· 1 shared D. Le Guennec· 1 shared E. Mery· 1 shared F. Caldefie-Chezet· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Coste

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The EO771 mammary cancer cell line displays a luminal B phenotype and it is sensitive to anti-estrogen treatments

A. Le Naour, Y. Koffi, M. Diab, D. Le Guennec, S. Rouge, S. Aldekwer, N. Goncalves-Mendes, J. Talvas, M.-C. Farges, F. Caldefie-Chezet, M.-P. Vasson, A. Rossary

The paper characterizes the EO771 mammary cancer cell line as luminal B subtype and shows its sensitivity to anti-estrogen treatments.

bioRxiv · Jul 25, 2019Cancer Biology

Mesenchymal stromal cells release CXCL1/2/8 and induce chemoresistance and macrophage polarization

B. Couderc, A. Le Naour, M. Prat, R. Mevel, B. Thibault, L. Lemaitre, H. Leray, M. Golzio, L. Lefevre, E. Mery, A. Martinez, G. Ferron, J.-P. Delord, A. Coste

This study identifies CXCL1/2/8 as factors released by cancer-associated mesenchymal stromal cells that induce chemoresistance and macrophage polarization, suggesting CXCR1/2 inhibition as a potential therapeutic strategy.

bioRxiv · Dec 4, 2018 · PreprintCancer Biology